Mayo Clinic: Plasmacytoma trials

The registry lists 26 Plasmacytoma studies with Mayo Clinic as lead sponsor. 0 are open to participants now and 15 have results posted.

Early Phase 1 1Phase 1 8Phase 2 19Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00772915Phase 2Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
• Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple MyelomaCompletedNCT00635154Phase 2Results posted
• Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
• Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00609167Phase 2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or AmyloidosisCompletedNCT00558896Phase 2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00478218Phase 2Results posted
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00477971Phase 3Results posted
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00477750Phase 1/2Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple MyelomaCompletedNCT00432458Phase 3Results posted
• Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
• Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeCompletedNCT02921893Early Phase 1
• Everolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00618345Phase 2
• Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00616720Phase 2
• Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantCompletedNCT00602706Phase 1/2
• Bevacizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00482495Phase 2
• Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone PainCompletedNCT00482378Phase 1/2
• Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00478075Phase 1/2
• Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00477815Phase 1
• PS-341 in Treating Patients With Advanced CancerCompletedNCT00006362Phase 1
• Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple MyelomaCompletedNCT00006219Phase 2
• High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First RelapseCompletedNCT00002630Phase 2